RxDoctor Payments Data

Sandeep Kapoor, MD

Internal Medicine · Studio City, CANPI 1689860165

Payments from drug & device makers

$5,299in general payments, 2019–2025

Across 276 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$2K
  • Collegium Pharmaceutical, Inc.$591
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$579
  • Regeneron Healthcare Solutions, Inc.$467
  • Merck$262
  • AbbVie$243
  • plus $694 from 11 others

What the payments were for

  • Food & beverage$5,277100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,299 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$241,721
Medicare patients
161
Services billed
2,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl43$81,896
EliquisApixaban96$62,827
EntrestoSacubitril/Valsartan28$19,077
LinzessLinaclotide13$16,152
XareltoRivaroxaban18$15,651
Bydureon BciseExenatide Microspheres13$15,610
Xtampza ErOxycodone Myristate14$15,482
RybelsusSemaglutide15$14,548
OzempicSemaglutide13$12,457
LivaloPitavastatin Calcium20$11,453
MyrbetriqMirabegron18$8,507
VascepaIcosapent Ethyl17$7,731
JanuviaSitagliptin Phosphate13$7,397
BrilintaTicagrelor12$5,436
Kombiglyze XrSaxagliptin Hcl/Metformin Hcl11$3,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$62,82796 claims
Novo NordiskRybelsus, Ozempic$73$27,00528 claims
AbbVieLinzess, Synthroid$243$18,58941 claims
Collegium Pharmaceutical, Inc.Xtampza Er$591$15,48214 claims
MerckJanuvia$262$7,39713 claims
AstraZenecaBrilinta$27$5,43612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Studio City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →